Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amphastar Pharmaceuticals

28.97
+0.16000.56%
Volume:74.40K
Turnover:2.14M
Market Cap:1.38B
PE:9.47
High:29.24
Open:28.60
Low:28.22
Close:28.81
Loading ...

Company Profile

Company Name:
Amphastar Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
2028
Office Location:
11570 6th Street,Rancho Cucamonga,California,United States
Zip Code:
91730
Fax:
- -
Introduction:
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Directors

Name
Position
Jack Yongfeng Zhang
Chief Executive Officer, Chief Scientific Officer and Director
Mary Ziping Luo
Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors
Jason B. Shandell
President, General Counsel and Director
Michael A. Zasloff
Lead Independent Director
Floyd F. Petersen
Director
Howard Lee
Director
Richard Koo
Director
Richard Prins
Director
Stephen B. Shohet
Director

Shareholders

Name
Position
Jack Yongfeng Zhang
Chief Executive Officer, Chief Scientific Officer and Director
Mary Ziping Luo
Chief Operating Officer, Chief Scientist and Chairman of the Board of Directors
William J. Peters
Chief Financial Officer, Senior Vice President, and
Diane G. Gerst
Executive Vice President of Quality Assurance and Regulatory
Jason B. Shandell
President, General Counsel and Director
Rong Zhou
Executive Vice President of Production